• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-146b 通过 FBXL10 促进卵巢癌细胞增殖和增加化疗敏感性,但抑制细胞迁移和侵袭。

miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.

机构信息

Department of Immunology, Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China.

Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.

出版信息

Cell Death Dis. 2018 Nov 8;9(11):1123. doi: 10.1038/s41419-018-1093-9.

DOI:10.1038/s41419-018-1093-9
PMID:30409964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6224598/
Abstract

Epithelial ovarian carcinoma (EOC) is the most lethal gynecologic malignancy. However, the molecular mechanisms remain unclear. In this study, we found that miR-146b was downregulated in EOC and its expression level was negatively correlated with the pathological staging. Follow-up functional experiments illustrated that overexpression of miR-146b significantly inhibited cell migration and invasion, and increased cell proliferation, but it also improved the response to chemotherapeutic agents. Mechanistically, we demonstrated that miR-146b exerted its function mainly through inhibiting F-box and leucine-rich repeat protein 10 (FBXL10), and upregulated the Cyclin D1, vimentin (VIM), and zona-occludens-1 (ZO-1) expression in EOC. These findings indicate that miR-146b-FBXL10 axis is an important epigenetic regulation pathway in EOC. Low miR-146b may contribute to cancer progression from primary stage to advanced stage, and may be the promising therapeutic target of EOC.

摘要

上皮性卵巢癌 (EOC) 是最致命的妇科恶性肿瘤。然而,其分子机制尚不清楚。在本研究中,我们发现 miR-146b 在 EOC 中表达下调,其表达水平与病理分期呈负相关。后续的功能实验表明,miR-146b 的过表达显著抑制了细胞迁移和侵袭,同时增加了细胞增殖,但也提高了对化疗药物的反应。从机制上讲,我们证明 miR-146b 主要通过抑制 F-box 和富含亮氨酸重复蛋白 10 (FBXL10) 发挥其功能,并在上皮性卵巢癌中上调细胞周期蛋白 D1、波形蛋白 (VIM) 和紧密连接蛋白-1 (ZO-1) 的表达。这些发现表明 miR-146b-FBXL10 轴是 EOC 中重要的表观遗传调控途径。低水平的 miR-146b 可能导致癌症从早期阶段进展到晚期阶段,并且可能是 EOC 有前途的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/b0ddef0deec1/41419_2018_1093_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/9fc609155f07/41419_2018_1093_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/a964f9757039/41419_2018_1093_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/2b283b9b3fed/41419_2018_1093_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/b0ddef0deec1/41419_2018_1093_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/9fc609155f07/41419_2018_1093_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/a964f9757039/41419_2018_1093_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/2b283b9b3fed/41419_2018_1093_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db8/6224598/b0ddef0deec1/41419_2018_1093_Fig7_HTML.jpg

相似文献

1
miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.miR-146b 通过 FBXL10 促进卵巢癌细胞增殖和增加化疗敏感性,但抑制细胞迁移和侵袭。
Cell Death Dis. 2018 Nov 8;9(11):1123. doi: 10.1038/s41419-018-1093-9.
2
MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.MicroRNA-302 通过调控卵巢癌细胞中的 ATAD2 抑制上皮-间质转化和顺铂耐药性。
Exp Cell Res. 2020 Nov 1;396(1):112241. doi: 10.1016/j.yexcr.2020.112241. Epub 2020 Aug 21.
3
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.赖氨酸去甲基化酶 2A 通过调节 PI3K 通路和逆转上皮-间充质转化促进卵巢癌的进展。
Oncol Rep. 2019 Feb;41(2):917-927. doi: 10.3892/or.2018.6888. Epub 2018 Nov 27.
4
SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.SMAD3 通过诱导 STYK1 的转录促进 EMT 过程,提高卵巢癌细胞对紫杉醇的耐受性。
J Cell Biochem. 2019 Jun;120(6):10796-10811. doi: 10.1002/jcb.28371. Epub 2019 Jan 30.
5
miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.miR-874-3p 通过调节上皮性卵巢癌细胞中 NF-κB/凋亡抑制蛋白信号通路来减轻顺铂耐药性。
Mol Cell Biochem. 2022 Jan;477(1):307-317. doi: 10.1007/s11010-021-04271-6. Epub 2021 Oct 30.
6
Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.miR-503的下调通过靶向PI3K p85促进卵巢癌耐药性的发展。
Arch Gynecol Obstet. 2018 Mar;297(3):699-707. doi: 10.1007/s00404-018-4649-0. Epub 2018 Jan 11.
7
MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.miR-152 和 miR-185 通过直接靶向 DNMT1 共同促进卵巢癌细胞对顺铂的敏感性:一种不依赖地西他滨的新型表观遗传治疗方法。
Oncogene. 2014 Jan 16;33(3):378-86. doi: 10.1038/onc.2012.575. Epub 2013 Jan 14.
8
BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.BRMS1L 通过抑制β-catenin-wnt 通路抑制卵巢癌转移。
Exp Cell Res. 2018 Oct 1;371(1):214-221. doi: 10.1016/j.yexcr.2018.08.013. Epub 2018 Aug 15.
9
Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.微小RNA-630的下调抑制人卵巢癌细胞的增殖和侵袭并增强其化疗敏感性。
Genet Mol Res. 2015 Jul 31;14(3):8766-77. doi: 10.4238/2015.July.31.25.
10
IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.白细胞介素-6受体/信号转导和转录激活因子3/微小RNA-204反馈环促成上皮性卵巢癌细胞的顺铂耐药性。
Oncotarget. 2017 Jun 13;8(24):39154-39166. doi: 10.18632/oncotarget.16610.

引用本文的文献

1
Exosomes Derived from Induced and Wharton's Jelly-Derived Mesenchymal Stem Cells Promote Senescence-like Features and Migration in Cancer Cells.源自诱导型和沃顿胶间充质干细胞的外泌体促进癌细胞的衰老样特征和迁移。
Int J Mol Sci. 2025 Jun 26;26(13):6178. doi: 10.3390/ijms26136178.
2
Distinct anticancer properties of exosomes from induced mesenchymal stem cells vs. bone marrow-derived stem cells in MCF7 and A549 models.在MCF7和A549模型中,诱导间充质干细胞来源的外泌体与骨髓来源的干细胞来源的外泌体具有不同的抗癌特性。
Biomed Rep. 2025 May 14;23(1):116. doi: 10.3892/br.2025.1994. eCollection 2025 Jul.
3
The interaction between ΔNp63α and TAp63α, mediated by miR-205-5p, inhibits the migration of lung adenocarcinoma cells.

本文引用的文献

1
Major clinical research advances in gynecologic cancer in 2017.2017 年妇科癌症的主要临床研究进展。
J Gynecol Oncol. 2018 Mar;29(2):e31. doi: 10.3802/jgo.2018.29.e31.
2
In vitro and in vivo evaluation of folate receptor-targeted a novel magnetic drug delivery system for ovarian cancer therapy.叶酸受体靶向新型磁性药物递送系统用于卵巢癌治疗的体内外评价。
Artif Cells Nanomed Biotechnol. 2018;46(sup1):926-937. doi: 10.1080/21691401.2018.1439838. Epub 2018 Feb 19.
3
Up-regulated WDR5 promotes gastric cancer formation by induced cyclin D1 expression.
由miR-205-5p介导的ΔNp63α与TAp63α之间的相互作用抑制肺腺癌细胞的迁移。
Sci Rep. 2025 Apr 3;15(1):11501. doi: 10.1038/s41598-025-95206-4.
4
Molecular mechanisms of cisplatin resistance in ovarian cancer.卵巢癌中顺铂耐药的分子机制。
Genes Dis. 2023 Aug 2;11(6):101063. doi: 10.1016/j.gendis.2023.06.032. eCollection 2024 Nov.
5
A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs.在由微小RNA调控的甲状腺乳头状癌(PTC)和非侵袭性滤泡性甲状腺肿瘤伴乳头状核特征(NIFTP)中,存在一种表皮生长因子受体表达的新范式。
Front Oncol. 2023 Apr 11;13:1080008. doi: 10.3389/fonc.2023.1080008. eCollection 2023.
6
Deciphering sex-specific miRNAs as heat-recorders in zebrafish.解析作为鱼类热记录器的性别特异性 miRNA。
Sci Rep. 2022 Nov 4;12(1):18722. doi: 10.1038/s41598-022-21864-3.
7
Epigenetic Regulation Towards Acquired Drug Resistance in Cancer.癌症获得性耐药的表观遗传调控。
Subcell Biochem. 2022;100:473-502. doi: 10.1007/978-3-031-07634-3_14.
8
The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance.E3泛素连接酶在卵巢癌化疗耐药中的新作用
Cancer Drug Resist. 2021 Jun 19;4(2):365-381. doi: 10.20517/cdr.2020.115. eCollection 2021.
9
Identification of the toxic 6mer seed consensus for human cancer cells.鉴定人类癌细胞毒性 6mer 种子共识。
Sci Rep. 2022 Mar 24;12(1):5130. doi: 10.1038/s41598-022-09051-w.
10
Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach.TRPC1表达的调节可预测乳腺癌对阿霉素和磁场疗法的敏感性:迈向精准医学方法的过渡
Front Oncol. 2022 Jan 24;11:783803. doi: 10.3389/fonc.2021.783803. eCollection 2021.
WDR5 的上调通过诱导 cyclin D1 的表达促进胃癌的形成。
J Cell Biochem. 2018 Apr;119(4):3304-3316. doi: 10.1002/jcb.26491. Epub 2017 Dec 26.
4
Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.卵巢癌上皮-间质表型可塑性的复杂决定因素
Cancers (Basel). 2017 Aug 9;9(8):104. doi: 10.3390/cancers9080104.
5
Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration.协同的 IL-6 和 IL-8 旁分泌信号通路提示了抑制肿瘤细胞迁移的策略。
Nat Commun. 2017 May 26;8:15584. doi: 10.1038/ncomms15584.
6
The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer.外泌体在上皮性卵巢癌中的新兴作用及治疗潜力
Mol Cancer. 2017 May 15;16(1):92. doi: 10.1186/s12943-017-0659-y.
7
High-grade serous carcinoma of tubo-ovarian origin: recent developments.卵巢输卵管来源的高级别浆液性癌:最新进展。
Histopathology. 2017 Sep;71(3):339-356. doi: 10.1111/his.13248. Epub 2017 Jul 18.
8
KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation.KDM2B/FBXL10在有丝分裂原刺激下将c-Fos靶向泛素化和降解。
Oncogene. 2016 Aug 11;35(32):4179-90. doi: 10.1038/onc.2015.482. Epub 2016 Jan 4.
9
FBXL10 contributes to the progression of nasopharyngeal carcinoma via involving in PI3K/mTOR pathway.FBXL10 通过参与 PI3K/mTOR 通路促进鼻咽癌的进展。
Neoplasma. 2015;62(6):925-31. doi: 10.4149/neo_2015_112.
10
Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.Fbxl10在小鼠造血干细胞中的过表达会引发白血病,这涉及代谢激活和Nsg2的上调。
Blood. 2015 May 28;125(22):3437-46. doi: 10.1182/blood-2014-03-562694. Epub 2015 Apr 14.